phrykt

Assembly Biosciences, Inc. (ASMB): who owns it and who trades it

As of Nov 16, 2026, ASMB insiders reported 11 open-market sales worth $201K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason A Okazaki (CEO), with $122K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Assembly Biosciences

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ASMB

93 funds and institutions reported ASMB shares worth $516M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Gilead Sciences, Inc. with 31.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Gilead Sciences, Inc.31.4%
Farallon Capital Management, L.l.c.10.1%
Paradigm Biocapital Advisors LP9.8%
Commodore Capital LP8.9%
Ra Capital Management, L.P.6.4%
Jupiter Topco LLC5.4%
BlackRock, Inc.4.8%
Parkman Healthcare Partners LLC4.5%
Vanguard Capital Management LLC3.5%
Point72 Asset Management, L.P.2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Gilead Sciences, Inc.4.98M31.38%$137M+10%
Farallon Capital Management, L.l.c.1.60M10.12%$44.1M+31%
Paradigm Biocapital Advisors LP1.55M9.79%$42.7M+134%
Commodore Capital LP1.42M8.92%$38.9M+42%
Ra Capital Management, L.P.1.02M6.43%$28MNo change
Jupiter Topco LLC849,3095.35%$23.4MNew
BlackRock, Inc.766,8194.83%$21.1M+278%
Parkman Healthcare Partners LLC721,1814.55%$19.8M+75%
Vanguard Capital Management LLC558,9423.52%$15.4M+14%
Point72 Asset Management, L.P.460,5932.90%$12.7M+34%
Seven Fleet Capital Management LP433,1472.73%$11.9M+671%
Millennium Management LLC298,8071.88%$8.2M+28%
Geode Capital Management, LLC280,4241.77%$7.7M+111%
Schonfeld Strategic Advisors LLC242,1531.53%$6.7M+101%
Ameriprise Financial Inc230,0001.45%$6.3MNew
Dv Equities, LLC226,4151.43%$6.2MNew
Aberdeen Group plc207,0471.31%$5.7MNew
Affinity Asset Advisors, LLC190,0001.20%$5.2MNew
B Group, Inc.175,7061.11%$4.8MNo change
State Street Corp171,9311.08%$4.7M+203%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ASMB insiders reported $0 of open-market purchases and $201K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$201K
11 trades, 4 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 2, 2026
Filed Nov 3, 2026

Purchases and sales by month

$187K$187KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 2, 2026Jason A OkazakiCEOSale6,133$19.61$120KForm 4
Nov 2, 2026Jason A OkazakiCEOSale69$20.35$1.4KForm 4
Nov 2, 2026Anuj GaggarChief Medical OfficerSale2,564$19.61$50.3KForm 4
Nov 2, 2026Anuj GaggarChief Medical OfficerSale29$20.35$590Form 4
Nov 2, 2026Jeanette M BjorkquistPFO and PAOSale718$19.61$14.1KForm 4
Nov 2, 2026Jeanette M BjorkquistPFO and PAOSale9$20.35$183Form 4
Jun 17, 2026Jeanette M BjorkquistPFO and PAOSale29$23.25$674Form 4
Mar 30, 2026Jeanette M BjorkquistPFO and PAOSale16$27.49$440Form 4
Mar 30, 2026Jeanette M BjorkquistPFO and PAOSale312$26.65$8.3KForm 4
Mar 30, 2026Nicole S WhiteChief Manufacturing OffiSale9$27.49$247Form 4
Mar 30, 2026Nicole S WhiteChief Manufacturing OffiSale188$26.65$5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jason A OkazakiCEO and President, Director–$122KNov 2, 2026
Anuj GaggarChief Medical Officer–$50.9KNov 2, 2026
Jeanette M BjorkquistPFO and PAO–$23.7KNov 2, 2026
Nicole S WhiteChief Manufacturing Officer–$5.3KMar 30, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ASMB short interest

High short interest. 14.9% of ASMB shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 97%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.03M ASMB shares were sold short, 14.9% of the shares outstanding, up 4.1% from the report before. At the average daily volume of 178,424 shares, buying them all back would take about 17.0 trading days (days to cover).

Shares short, % of all shares

14.9%May 15Oct 3016.0%

Days to cover

17.0May 15Oct 3018.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.03M14.89%+4%178,42417.0
Oct 15, 20262.91M14.31%+3%263,10311.1
Sep 30, 20262.82M13.86%+35%412,9506.8
Sep 15, 20262.10M10.29%-1%334,7476.3
Aug 31, 20262.12M10.41%-8%314,2726.8
Aug 14, 20262.31M11.37%-1%230,35710.1
Jul 31, 20262.34M14.73%+1%147,66115.8
Jul 15, 20262.31M14.58%-4%157,30214.7
Jun 30, 20262.41M15.18%+29%365,5636.6
Jun 15, 20261.87M11.76%+11%198,2859.4
May 29, 20261.68M10.62%+9%223,7377.5
May 15, 20261.54M9.73%-1%163,8589.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Assembly Biosciences company events

Assembly Biosciences filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Aug 14, 2026.

  1. Aug 14, 2026ResultsAmended an earlier report. Released financial results. Filing
  2. Aug 13, 2026DealCompleted a purchase or sale of a business or assets. Filing
  3. Jun 5, 2026LeadershipAmendment No. 3 to Amended and Restated 2018 Stock Incentive Plan At the Assembly Biosciences, Inc. Annual Meeting of Stockholders held on June 4, 2026,, the Company's stockholders approved Amendment No. 3 to the Assembly Biosciences, Inc. Amended and Restated 2018 Stock Incentive Plan to increase… Filing
  4. May 26, 2026AgreementAssembly Biosciences, Inc. entered into an underwriting agreement with Guggenheim Securities, LLC and UBS Securities LLC, as representatives of the several underwriters listed in Schedule A thereto, in connection with the issuance and sale, in an underwritten, registered offering, of: (1) 3,358,602… Filing
  5. May 22, 2026AnnouncementThe Company has plans to expand the clinical development of 6250, its oral entry inhibitor candidate for chronic HDV infection, into PBC and PSC, broadening the program into cholestatic liver diseases. 6250 is currently being evaluated for chronic HDV infection and has completed a Phase 1a clinical… Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Mar 30, 2026LeadershipThe Compensation Committee of the Board of Directors of Assembly Biosciences, Inc. approved a new cash bonus plan, the 2026 Corporate Bonus Plan. Filing
  8. Mar 19, 2026ResultsReleased financial results. Filing
  9. Dec 8, 2025AnnouncementABI-1179 The Company announced interim results from the 1179 Study. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Assembly Biosciences financials

Famous investors that hold ASMB

4 of the 50 well-known investors we track reported holding ASMB in their latest 13F filing. The largest position is Israel Englander's, worth $11.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026490,137$11.5M0.0%+64%
Ken Griffin · Citadel AdvisorsQ3 2026379,812$8.9M0.0%+296%
Steve Cohen · Point72 Asset ManagementQ3 2026362,728$8.5M0.0%-21%
Jim Simons · Renaissance TechnologiesQ3 2026112,017$2.6M0.0%+184%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ASMB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A3.3%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A3.3%

Questions about Assembly Biosciences, Inc. (ASMB) stock

Who owns the most ASMB stock?

The largest reported owner of Assembly Biosciences, Inc. (ASMB) is Gilead Sciences, Inc., with 31.4% of the company. In total, 93 funds and institutions reported holding ASMB at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ASMB insiders buying or selling?

In the last 12 months, ASMB insiders reported no open-market purchases and 11 sales worth $201K. The latest trade was on Nov 2, 2026. See every trade.

What is the short interest in ASMB?

As of Oct 30, 2026, 3.03M ASMB shares were sold short, 14.9% of the shares outstanding, up 4.1% from the report before. At the average daily volume of 178,424 shares, buying them all back would take about 17.0 trading days (days to cover). See the history.

Which famous investors hold ASMB?

4 of the 50 well-known investors we track reported ASMB in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $11.5M. See all holders.

Executive pay

Assembly Biosciences's chief executive was paid a total of $2.5M for the year ended Dec 31, 2025, up 41% from $1.8M the year before. In the last 12 months, Assembly Biosciences's executives and directors bought no stock on the open market and sold $201K.

Chief executive, total pay$2.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$5.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.